Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.33
NYSE:A's Cash-to-Debt is ranked lower than
61% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. NYSE:A: 1.33 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:A' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.67  Med: 1.33 Max: No Debt
Current: 1.33
Equity-to-Asset 0.57
NYSE:A's Equity-to-Asset is ranked lower than
57% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NYSE:A: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:A' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.5 Max: 0.71
Current: 0.57
0.33
0.71
Debt-to-Equity 0.42
NYSE:A's Debt-to-Equity is ranked lower than
58% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. NYSE:A: 0.42 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:A' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.43 Max: 1.16
Current: 0.42
0.02
1.16
Debt-to-EBITDA 1.06
NYSE:A's Debt-to-EBITDA is ranked lower than
52% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. NYSE:A: 1.06 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:A' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.06  Med: 2.14 Max: 11.3
Current: 1.06
1.06
11.3
Interest Coverage 10.53
NYSE:A's Interest Coverage is ranked lower than
66% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. NYSE:A: 10.53 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:A' s Interest Coverage Range Over the Past 10 Years
Min: 0.53  Med: 7.19 Max: 12.45
Current: 10.53
0.53
12.45
Piotroski F-Score: 7
Altman Z-Score: 5.59
Beneish M-Score: -2.09
WACC vs ROIC
11.44%
31.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 18.74
NYSE:A's Operating Margin % is ranked higher than
88% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. NYSE:A: 18.74 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:A' s Operating Margin % Range Over the Past 10 Years
Min: 1.05  Med: 13.35 Max: 18.81
Current: 18.74
1.05
18.81
Net Margin % 15.42
NYSE:A's Net Margin % is ranked higher than
90% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. NYSE:A: 15.42 )
Ranked among companies with meaningful Net Margin % only.
NYSE:A' s Net Margin % Range Over the Past 10 Years
Min: -0.69  Med: 13.06 Max: 18.85
Current: 15.42
-0.69
18.85
ROE % 26.76
NYSE:A's ROE % is ranked higher than
80% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. NYSE:A: 26.76 )
Ranked among companies with meaningful ROE % only.
NYSE:A' s ROE % Range Over the Past 10 Years
Min: -1.22  Med: 14.55 Max: 26.86
Current: 26.76
-1.22
26.86
ROA % 14.81
NYSE:A's ROA % is ranked higher than
81% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. NYSE:A: 14.81 )
Ranked among companies with meaningful ROA % only.
NYSE:A' s ROA % Range Over the Past 10 Years
Min: -0.42  Med: 7.41 Max: 14.81
Current: 14.81
-0.42
14.81
ROC (Joel Greenblatt) % 133.29
NYSE:A's ROC (Joel Greenblatt) % is ranked higher than
91% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. NYSE:A: 133.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:A' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.79  Med: 44.69 Max: 133.29
Current: 133.29
7.79
133.29
3-Year Revenue Growth Rate 4.60
NYSE:A's 3-Year Revenue Growth Rate is ranked lower than
55% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. NYSE:A: 4.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:A' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: 4.2 Max: 18.4
Current: 4.6
-22.9
18.4
3-Year EBITDA Growth Rate 16.20
NYSE:A's 3-Year EBITDA Growth Rate is ranked lower than
52% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. NYSE:A: 16.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:A' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -27.7  Med: 6.2 Max: 76.6
Current: 16.2
-27.7
76.6
3-Year EPS without NRI Growth Rate 44.90
NYSE:A's 3-Year EPS without NRI Growth Rate is ranked higher than
80% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. NYSE:A: 44.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:A' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -37.7  Med: 15.1 Max: 135.6
Current: 44.9
-37.7
135.6
GuruFocus has detected 5 Warning Signs with Agilent Technologies Inc NYSE:A.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:A's 30-Y Financials

Financials (Next Earnings Date: 2018-02-14)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

A Guru Trades in Q4 2016

Jim Simons 766,200 sh (+6079.03%)
Steven Cohen 370,300 sh (+1002.08%)
Paul Tudor Jones 13,571 sh (+50.94%)
Keeley Asset Management Corp 24,025 sh (+12.35%)
Ron Baron 28,000 sh (unchged)
Stanley Druckenmiller Sold Out
PRIMECAP Management 4,654,830 sh (-0.57%)
Mario Gabelli 170,400 sh (-0.81%)
Columbia Wanger 588,093 sh (-16.38%)
Vanguard Health Care Fund 1,889,350 sh (-25.63%)
Joel Greenblatt 324,174 sh (-31.16%)
» More
Q1 2017

A Guru Trades in Q1 2017

Pioneer Investments 50,326 sh (New)
Steven Cohen 996,237 sh (+169.04%)
Columbia Wanger 621,835 sh (+5.74%)
PRIMECAP Management 4,765,730 sh (+2.38%)
Vanguard Health Care Fund 1,889,350 sh (unchged)
Ron Baron 28,000 sh (unchged)
Mario Gabelli 165,000 sh (-3.17%)
Jim Simons 559,100 sh (-27.03%)
Paul Tudor Jones 9,073 sh (-33.14%)
Joel Greenblatt 67,191 sh (-79.27%)
» More
Q2 2017

A Guru Trades in Q2 2017

Paul Tudor Jones 13,077 sh (+44.13%)
Steven Cohen 1,306,668 sh (+31.16%)
PRIMECAP Management 5,057,020 sh (+6.11%)
Ron Baron 28,000 sh (unchged)
Pioneer Investments Sold Out
Jim Simons Sold Out
Vanguard Health Care Fund 1,667,550 sh (-11.74%)
Mario Gabelli 145,400 sh (-11.88%)
Columbia Wanger 330,675 sh (-46.82%)
Joel Greenblatt 28,923 sh (-56.95%)
» More
Q3 2017

A Guru Trades in Q3 2017

Ken Fisher 9,493 sh (New)
Jim Simons 557,700 sh (New)
Jeremy Grantham 25,900 sh (New)
Caxton Associates 3,500 sh (New)
Joel Greenblatt 45,934 sh (+58.81%)
Paul Tudor Jones 20,704 sh (+58.32%)
Ron Baron 28,000 sh (unchged)
Steven Cohen Sold Out
PRIMECAP Management 4,889,900 sh (-3.30%)
Vanguard Health Care Fund 1,486,550 sh (-10.85%)
Columbia Wanger 285,901 sh (-13.54%)
Mario Gabelli 117,400 sh (-19.26%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:A

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-09-30 Reduce -10.85%0.02%$58.57 - $66.17 $ 68.6910%1,486,550
Mario Gabelli 2017-09-30 Reduce -19.26%0.01%$58.57 - $66.17 $ 68.6910%117,400
Joel Greenblatt 2017-09-30 Add 58.81%0.01%$58.57 - $66.17 $ 68.6910%45,934
Ken Fisher 2017-09-30 New Buy$58.57 - $66.17 $ 68.6910%9,493
Vanguard Health Care Fund 2017-06-30 Reduce -11.74%0.03%$52.33 - $60.81 $ 68.6921%1,667,550
Mario Gabelli 2017-06-30 Reduce -11.88%0.01%$52.33 - $60.81 $ 68.6921%145,400
Joel Greenblatt 2017-06-30 Reduce -56.95%0.03%$52.33 - $60.81 $ 68.6921%28,923
Mario Gabelli 2017-03-31 Reduce -3.17%$46.49 - $54.1 $ 68.6936%165,000
Joel Greenblatt 2017-03-31 Reduce -79.27%0.15%$46.49 - $54.1 $ 68.6936%67,191
Vanguard Health Care Fund 2016-12-31 Reduce -25.63%0.07%$43.21 - $47.69 $ 68.6951%1,889,350
Joel Greenblatt 2016-12-31 Reduce -31.16%0.09%$43.21 - $47.69 $ 68.6951%324,174
Mario Gabelli 2016-12-31 Reduce -0.81%$43.21 - $47.69 $ 68.6951%170,400
Keeley Asset Management Corp 2016-12-31 Add 12.35%0.01%$43.21 - $47.69 $ 68.6951%24,025
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3825
Compare:NYSE:Q, NYSE:LH, NAS:IDXX, TSE:6869, NYSE:DGX, XPAR:ERF, SZSE:300676, XPAR:BIM, NYSE:PKI, NAS:QGEN, NYSE:BIO, NAS:ICLR, XTER:SRT3, NAS:EXAS, NAS:INCR, NYSE:CRL, NAS:PRAH, MIL:DIA, NAS:BRKR, XTER:AFX » details
Traded in other countries:AG8.Germany,
Headquarter Location:USA
Agilent Technologies Inc is engaged in life sciences, diagnostics and applied chemical markets. The company provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading health-care firm. Today, Agilent's measurement technologies serve a broad base of customers within three operating segments: life science and applied equipment (49% of sales), cross lab (which includes consumables and services at 34%), and diagnostics and genomics (17%). The United States and Europe account for 34% and 27% of revenue, respectively, with China and Japan accounting for the majority of remaining sales. Agilent is headquartered in California.

Ratios

vs
industry
vs
history
PE Ratio 20.57
A's PE Ratio is ranked higher than
53% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. A: 20.57 )
Ranked among companies with meaningful PE Ratio only.
A' s PE Ratio Range Over the Past 10 Years
Min: 5.2  Med: 16.68 Max: 48.52
Current: 20.57
5.2
48.52
Forward PE Ratio 26.60
A's Forward PE Ratio is ranked lower than
64% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.26 vs. A: 26.60 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 20.57
A's PE Ratio without NRI is ranked higher than
56% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.88 vs. A: 20.57 )
Ranked among companies with meaningful PE Ratio without NRI only.
A' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.2  Med: 16.97 Max: 301.43
Current: 20.57
5.2
301.43
Price-to-Owner-Earnings 19.32
A's Price-to-Owner-Earnings is ranked lower than
51% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.21 vs. A: 19.32 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
A' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.01  Med: 16.86 Max: 194.42
Current: 19.32
6.01
194.42
PB Ratio 4.64
A's PB Ratio is ranked lower than
54% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. A: 4.64 )
Ranked among companies with meaningful PB Ratio only.
A' s PB Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.75 Max: 4.72
Current: 4.64
1.22
4.72
PS Ratio 2.89
A's PS Ratio is ranked lower than
61% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. A: 2.89 )
Ranked among companies with meaningful PS Ratio only.
A' s PS Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.91 Max: 7.73
Current: 2.89
0.59
7.73
Price-to-Free-Cash-Flow 31.38
A's Price-to-Free-Cash-Flow is ranked lower than
59% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. A: 31.38 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
A' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.4  Med: 15.32 Max: 68.05
Current: 31.38
5.4
68.05
Price-to-Operating-Cash-Flow 25.17
A's Price-to-Operating-Cash-Flow is ranked lower than
63% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. A: 25.17 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
A' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.31  Med: 12.53 Max: 39.2
Current: 25.17
4.31
39.2
EV-to-EBIT 14.08
A's EV-to-EBIT is ranked higher than
57% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. A: 14.08 )
Ranked among companies with meaningful EV-to-EBIT only.
A' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 14.1 Max: 249.8
Current: 14.08
4.9
249.8
EV-to-EBITDA 11.32
A's EV-to-EBITDA is ranked higher than
55% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. A: 11.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
A' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 11.4 Max: 31.7
Current: 11.32
4
31.7
EV-to-Revenue 2.77
A's EV-to-Revenue is ranked lower than
56% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. A: 2.77 )
Ranked among companies with meaningful EV-to-Revenue only.
A' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.7  Med: 1.9 Max: 7.6
Current: 2.77
0.7
7.6
Shiller PE Ratio 32.83
A's Shiller PE Ratio is ranked higher than
69% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 49.53 vs. A: 32.83 )
Ranked among companies with meaningful Shiller PE Ratio only.
A' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.84  Med: 20.91 Max: 46.42
Current: 32.83
9.84
46.42
Current Ratio 3.30
A's Current Ratio is ranked higher than
61% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. A: 3.30 )
Ranked among companies with meaningful Current Ratio only.
A' s Current Ratio Range Over the Past 10 Years
Min: 1.92  Med: 2.43 Max: 3.85
Current: 3.3
1.92
3.85
Quick Ratio 2.85
A's Quick Ratio is ranked higher than
62% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. A: 2.85 )
Ranked among companies with meaningful Quick Ratio only.
A' s Quick Ratio Range Over the Past 10 Years
Min: 0.99  Med: 1.95 Max: 3.28
Current: 2.85
0.99
3.28
Days Inventory 99.04
A's Days Inventory is ranked lower than
55% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.37 vs. A: 99.04 )
Ranked among companies with meaningful Days Inventory only.
A' s Days Inventory Range Over the Past 10 Years
Min: 91.25  Med: 98.95 Max: 191.04
Current: 99.04
91.25
191.04
Days Sales Outstanding 34.08
A's Days Sales Outstanding is ranked higher than
61% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. A: 34.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
A' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.08  Med: 54.8 Max: 84.27
Current: 34.08
34.08
84.27
Days Payable 54.46
A's Days Payable is ranked lower than
58% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. A: 54.46 )
Ranked among companies with meaningful Days Payable only.
A' s Days Payable Range Over the Past 10 Years
Min: 43.61  Med: 52.46 Max: 79.36
Current: 54.46
43.61
79.36

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.77
A's Dividend Yield % is ranked lower than
56% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.89 vs. A: 0.77 )
Ranked among companies with meaningful Dividend Yield % only.
A' s Dividend Yield % Range Over the Past 10 Years
Min: 0.31  Med: 1.1 Max: 1.42
Current: 0.77
0.31
1.42
Dividend Payout Ratio 0.26
A's Dividend Payout Ratio is ranked higher than
68% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 0.26 )
Ranked among companies with meaningful Dividend Payout Ratio only.
A' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.09  Med: 0.32 Max: 0.77
Current: 0.26
0.09
0.77
Forward Dividend Yield % 0.87
A's Forward Dividend Yield % is ranked lower than
64% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. A: 0.87 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.11
A's 5-Year Yield-on-Cost % is ranked lower than
73% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. A: 1.11 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
A' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.45  Med: 1.59 Max: 2.05
Current: 1.11
0.45
2.05
3-Year Average Share Buyback Ratio 0.90
A's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. A: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
A' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.5  Med: 0.9 Max: 11.4
Current: 0.9
-2.5
11.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 39.48
A's Price-to-Net-Current-Asset-Value is ranked lower than
98% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.01 vs. A: 39.48 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
A' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.8  Med: 11.23 Max: 189.43
Current: 39.48
2.8
189.43
Price-to-Tangible-Book 12.05
A's Price-to-Tangible-Book is ranked lower than
79% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.57 vs. A: 12.05 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
A' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.1  Med: 3.77 Max: 12.05
Current: 12.05
1.1
12.05
Price-to-Intrinsic-Value-Projected-FCF 2.10
A's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
52% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. A: 2.10 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
A' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.18 Max: 2.84
Current: 2.1
0.62
2.84
Price-to-Median-PS-Value 1.51
A's Price-to-Median-PS-Value is ranked lower than
91% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. A: 1.51 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
A' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 0.95 Max: 1.79
Current: 1.51
0.37
1.79
Price-to-Graham-Number 3.32
A's Price-to-Graham-Number is ranked lower than
64% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.40 vs. A: 3.32 )
Ranked among companies with meaningful Price-to-Graham-Number only.
A' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1  Med: 2.34 Max: 4.76
Current: 3.32
1
4.76
Earnings Yield (Greenblatt) % 7.10
A's Earnings Yield (Greenblatt) % is ranked higher than
80% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. A: 7.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
A' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 7.1 Max: 20.2
Current: 7.1
0.4
20.2
Forward Rate of Return (Yacktman) % 4.72
A's Forward Rate of Return (Yacktman) % is ranked lower than
74% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.99 vs. A: 4.72 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
A' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -10.2  Med: 8.4 Max: 78.6
Current: 4.72
-10.2
78.6

More Statistics

Revenue (TTM) (Mil) $7,755.00
EPS (TTM) $ 3.34
Beta1.63
Short Percentage of Float0.68%
52-Week Range $42.92 - 70.81
Shares Outstanding (Mil)321.83

Analyst Estimate

Oct18 Oct19 Oct20
Revenue (Mil $) 4,729 4,991 5,290
EPS ($) 2.59 2.77 3.08
EPS without NRI ($) 2.59 2.77 3.08
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.58%
Dividends per Share ($) 0.59 0.66 0.66

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}